To explore the effect of tiotropium bromide combined with budesonide formoterol on elderly patients with chronic obstructive pulmonary disease (COPD).

Using the random number table method, the patients with COPD admitted to our hospital from January 2020 to November 2023 were divided into two groups: the control group received conventional treatment and used budesonide formoterol; the other group received the same treatment as the control group plus tiotropium bromide, serving as the experimental group. The blood gas analysis indicators, inflammation-related indicators, quality of life, clinical efficacy, and safety were compared between the two groups.

After treatment, arterial partial pressure of oxygen (PaO₂), generic quality of life inventory 74 (GQOLI-74) scores in the experimental group increased, while partial pressure of carbon dioxide (PaCO₂), interleukin-6 (IL-6), C-reactive protein (CRP) and procalcitonin (PCT) decreased, which were more significant than those in the control group(P<0.05). The experimental group’s overall efficacy rate was 98.33%, significantly better than the control group’s 80.00% (P<0.05). There was no statistically significant difference in adverse reactions between the experimental group (15.00%) and the control group (10.00%) (P>0.05).

Tiotropium bromide in combination with budesonide formoterol can effectively regulate blood gas analysis and the level of inflammation, improve quality of life and enhance clinical efficacy.